Docetaxel Injection, Solution
Product Images NDC 67457-531

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 67457-531). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Image 1)

Chemical structure of Docetaxel anhydrous, the active ingredient in Docetaxel injection, solution. The diagram shows the detailed molecular arrangement including rings, hydroxyl groups, and ester linkages characteristic of the compound.*

FDA Label Image

Figure-9 (Image 10)

A survival probability curve graph depicting survival time in months on the x-axis and survival probability percentage on the y-axis. Two lines represent different groups labeled TPF and PF, showing their respective survival probabilities over time up to 72 months.*

FDA Label Image

Figure 10 (Image 11)

A survival probability plot showing patient survival over time in months, comparing two groups labeled TPF (n=255) and PF (n=246). The y-axis represents survival probability (%) from 0 to 100%, and the x-axis shows survival time up to 72 months. A table below the chart indicates the number of patients at risk at various time points for each group.*

FDA Label Image

Carton (Image 12)

Packaging label for Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) by Mylan Institutional LLC. The label includes cautionary statements about cytotoxicity and concentration checks, directions for intravenous use only, and storage instructions. It indicates the product is sterile, available as a multiple-dose vial, and manufactured in India.*

FDA Label Image

Figure 1 (Image 2)

A line graph comparing disease-free survival (DFS) probability over time in months for two treatments labeled TAC and FAC. The graph shows DFS probability on the vertical axis (0% to 100%) and disease-free survival time in months on the horizontal axis (0 to 66 months), illustrating survival trends for each treatment group.*

FDA Label Image

Figure 2 (Image 3)

A Kaplan-Meier survival curve chart comparing survival probabilities over time (in months) for two treatment groups labeled TAC and FAC. The y-axis represents survival probability percentage, and the x-axis represents survival time in months, with data points spanning from 0 to 66 months.*

FDA Label Image

Figure-3 (Image 4)

A Kaplan-Meier survival curve comparing cumulative probability of overall survival over time in months for two groups: T75 (solid line) and BSC (dashed line). The graph shows higher survival probability for the T75 group, with a log-rank p-value of 0.010 indicating statistical significance.*

FDA Label Image

Figure-4 (Image 5)

A survival curve graph showing cumulative probability on the vertical axis and survival time in months on the horizontal axis. Two lines represent different groups labeled T75 (solid line) and V/I (dashed line). The graph includes a log-rank p-value of 0.13 for overall survival comparison.*

FDA Label Image

Figure 5 (Image 6)

A survival curve graph depicting survival probability over survival time in months. Two lines represent different treatment groups labeled as T75 q3w and M q3w, showing a decline in survival probability from 1.0 to under 0.4 across 30 months.*

FDA Label Image

Figure-6 (Image 7)

A survival curve graph showing probability (%) on the y-axis and time (months) on the x-axis up to 24 months. Two plotted lines represent groups labeled TCF (solid line) and CF (dotted line), depicting their respective survival probabilities over time.*

FDA Label Image

Figure-7 (Image 8)

A survival curve chart showing survival probability (%) on the vertical axis and survival time in months on the horizontal axis. It compares two groups labeled TCF and CF, indicating their respective survival probabilities over time from 0 to 36 months.*

FDA Label Image

Figure-8 (Image 9)

A Kaplan-Meier curve showing progression-free survival (PFS) probability over time in months. The graph compares two groups, labeled TPF and PF, with PFS probability on the vertical axis and progression-free survival time on the horizontal axis, illustrating survival trends over approximately 42 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.